The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1.
Ming YiJing ZhangAnping LiMengke NiuYongxiang YanYing JiaoSuxia LuoPengfei ZhouKongming WuPublished in: Journal of hematology & oncology (2021)
Our results demonstrated that YM101 could simultaneously block TGF-β and PD-L1 pathways and had a superior anti-tumor effect compared to the monotherapies.